We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-13.19%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.35B
AUM Growth
-$406M
Cap. Flow
+$12.3M
Cap. Flow %
0.52%
Top 10 Hldgs %
43.47%
Holding
145
New
11
Increased
25
Reduced
9
Closed
5

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$32.6M
2
LLY icon
Eli Lilly
LLY
+$25.1M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$22.3M
4
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$15.3M
5
WELL.PRI
Welltower Inc.
WELL.PRI
+$11.7M

Top Sells

Rank Stock Value
1
JNJ icon
Johnson & Johnson
JNJ
+$58.6M
2
TEVA icon
Teva Pharmaceutical Industries Limited
TEVA
+$38.9M
3
ILMN icon
Illumina
ILMN
+$13.4M
4
BXLT
BAXALTA INC COM STK (DE)
BXLT
+$12.5M
5
ALR
Alere Inc
ALR
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 89.09%
2 Miscellaneous 6.05%
3 Real Estate 4.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GSK icon
51
GSK
GSK
$100B
$11.6M 0.49%
228,000
– –
CPHD
52
DELISTED
Cepheid Inc
CPHD
$11.1M 0.47%
333,590
– –
ZBH icon
53
Zimmer Biomet
ZBH
$18.8B
$10.9M 0.46%
105,369
– –
ARDX icon
54
Ardelyx
ARDX
$878M
$10.8M 0.46%
1,389,370
+750,000
+117% +$7.38M
LTC
55
LTC Properties
LTC
$2.34B
$10.7M 0.46%
236,618
– –
UTHR icon
56
United Therapeutics
UTHR
$21.5B
$10.4M 0.44%
93,100
– –
IDXX icon
57
Idexx Laboratories
IDXX
$40.2B
$10.4M 0.44%
132,352
– –
AZN icon
58
AstraZeneca
AZN
$251B
$10M 0.43%
+177,900
New +$10.7M
SBRA icon
59
Sabra Healthcare REIT
SBRA
$5.18B
$9.16M 0.39%
456,190
– –
ALNY icon
60
Alnylam Pharmaceuticals
ALNY
$31.9B
$8.63M 0.37%
137,495
– –
ICLR icon
61
Icon
ICLR
$13.3B
$8.63M 0.37%
114,900
– –
CLLS
62
Cellectis
CLLS
$162M
$8.53M 0.36%
310,250
+103,000
+50% +$2.48M
NTRA icon
63
Natera
NTRA
$50.6B
$8.4M 0.36%
882,358
– –
ENDP
64
DELISTED
Endo International plc
ENDP
$8.06M 0.34%
286,348
– –
PBYI icon
65
Puma Biotechnology
PBYI
$477M
$7.64M 0.33%
260,200
– –
CNC icon
66
Centene
CNC
$33.4B
$7.39M 0.31%
240,000
– –
PVLA
67
Palvella Therapeutics
PVLA
$2.18B
$7.31M 0.31%
48,102
– –
JUNO
68
DELISTED
Juno Therapeutics, Inc.
JUNO
$6.93M 0.29%
182,000
– –
AVDL
69
DELISTED
Avadel Pharmaceuticals
AVDL
$6.89M 0.29%
624,288
+150,000
+32% +$1.49M
NVS icon
70
Novartis
NVS
$263B
$6.71M 0.29%
103,453
– –
FOMX
71
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$6.3M 0.27%
966,065
+313,920
+48% +$2.02M
ANAC
72
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$5.88M 0.25%
110,038
– –
HR
73
DELISTED
Healthcare Realty Trust Incorporated
HR
$5.78M 0.25%
187,224
– –
AKRX
74
DELISTED
Akorn Inc
AKRX
$5.77M 0.25%
245,235
+100,000
+69% +$2.63M
CYH icon
75
Community Health Systems
CYH
$419M
$5.64M 0.24%
368,411
– –
1 2
3
4 5

Similar funds

EST
EA Series Trust Newtown Square, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2016 Portfolio in Review

As of Q1 2016, Tekla Capital Management held 145 positions worth $2.35B, down 15% from $2.76B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Tekla Capital Management's Q1 2016 filing shows 11 new, 25 increased, 9 reduced and 5 closed positions. Its largest new stake was Jazz Pharmaceuticals: 179,091 shares worth $23.4M. The largest sale was Johnson & Johnson, an estimated $58.6M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 91% a quarter earlier, followed by Miscellaneous and Real Estate.

  • Tekla Capital Management's largest Q1 2016 buy was Jazz Pharmaceuticals: 179,091 shares worth $23.4M.
  • Tekla Capital Management added most to Medtronic in Q1 2016, an estimated $32.6M increase.
  • Tekla Capital Management's biggest Q1 2016 reduction was Johnson & Johnson, cutting an estimated $58.6M.
  • Tekla Capital Management fully exited BAXALTA INC COM STK (DE) in Q1 2016, selling an estimated $12.5M.
  • Tekla Capital Management's ten largest holdings make up 43% of its $2.35B portfolio in Q1 2016.
  • Tekla Capital Management opened 11 new positions and closed 5 in Q1 2016.
  • Tekla Capital Management's portfolio value fell 15% quarter-over-quarter to $2.35B.

Based on Tekla Capital Management's 13F filing for Q1 2016, filed 9 May 2016.